Ocugen, a biotechnology company specializing in gene therapies for blindness, announced it will present its innovative modifier gene therapy platform at several investor and industry conferences in June 2026. These events include the Noble Capital Markets Emerging Growth Virtual Equity Conference, Clinical Trials at the Summit, and the BIO International Convention. The presentations aim to highlight Ocugen's gene-agnostic approach to treating complex inherited retinal diseases such as retinitis pigmentosa and Stargardt disease. A webcast of the Noble presentation will be available on Ocugen's website, providing investors and stakeholders access to the latest updates on their clinical programs and development progress.
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
